Abstract
The prognosis of malignant glioma and metastatic brain tumours is still extremely poor, despite recent advances in therapeutic strategies with molecular-targeted agents. Poly(ADP-ribose) polymerase (PARP) inhibitors are a promising, novel class of anticancer drugs to be used either as single agents or in combination with chemotherapy and radiotherapy. PARP-1 and PARP-2 are the only PARP proteins that bind to DNA single strand breaks (SSBs), facilitating the repair process by the base excision repair. For this reason, PARPs have been extensively investigated as targets of novel drugs that may be used to enhance the antitumour activity of SSBs inducing agents, such as the methylating compound temozolomide, which is the drug of choice for glioblastoma, or ionizing radiations. Moreover, PARP inhibitors exert cytotoxic effects in monotherapy in BRCA mutated tumours, which are defective in the homologous recombination (HR) repair. Finally, recent studies have shown that inhibition of PARP function might also induce anti-angiogenic effects which might contribute to impair tumour growth.
Many clinical trials with PARP inhibitors are ongoing for the treatment of a variety of advanced solid tumours, including primary or secondary brain tumours. This review discusses the implications of targeting PARP on the design of new treatment regimens.
Keywords: Angiogenesis, chemoresistance, combination therapy, molecular-targeted therapy, poly(ADP-ribose) polymerase (PARP) inhibitors, telomere, temozolomide, topoisomerase I inhibitors, 6-Thioguanine, Base Excision Repair, DNA-dependent Protein Kinase, Homologous Recombination, Non Homologous DNA End Joining, Phosphate and Tension Homolog, Platelet-derived Growth Factor Receptor
Current Cancer Drug Targets
Title: Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Volume: 12 Issue: 3
Author(s): C. Leonetti, A. Biroccio, G. Graziani and L. Tentori
Affiliation:
Keywords: Angiogenesis, chemoresistance, combination therapy, molecular-targeted therapy, poly(ADP-ribose) polymerase (PARP) inhibitors, telomere, temozolomide, topoisomerase I inhibitors, 6-Thioguanine, Base Excision Repair, DNA-dependent Protein Kinase, Homologous Recombination, Non Homologous DNA End Joining, Phosphate and Tension Homolog, Platelet-derived Growth Factor Receptor
Abstract: The prognosis of malignant glioma and metastatic brain tumours is still extremely poor, despite recent advances in therapeutic strategies with molecular-targeted agents. Poly(ADP-ribose) polymerase (PARP) inhibitors are a promising, novel class of anticancer drugs to be used either as single agents or in combination with chemotherapy and radiotherapy. PARP-1 and PARP-2 are the only PARP proteins that bind to DNA single strand breaks (SSBs), facilitating the repair process by the base excision repair. For this reason, PARPs have been extensively investigated as targets of novel drugs that may be used to enhance the antitumour activity of SSBs inducing agents, such as the methylating compound temozolomide, which is the drug of choice for glioblastoma, or ionizing radiations. Moreover, PARP inhibitors exert cytotoxic effects in monotherapy in BRCA mutated tumours, which are defective in the homologous recombination (HR) repair. Finally, recent studies have shown that inhibition of PARP function might also induce anti-angiogenic effects which might contribute to impair tumour growth.
Many clinical trials with PARP inhibitors are ongoing for the treatment of a variety of advanced solid tumours, including primary or secondary brain tumours. This review discusses the implications of targeting PARP on the design of new treatment regimens.
Export Options
About this article
Cite this article as:
Leonetti C., Biroccio A., Graziani G. and Tentori L., Targeted Therapy for Brain Tumours: Role of PARP Inhibitors, Current Cancer Drug Targets 2012; 12 (3) . https://dx.doi.org/10.2174/156800912799277403
DOI https://dx.doi.org/10.2174/156800912799277403 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design Biomedical Application of Polymers: A Case Study of Non-CNS Drugs Becoming CNS Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Tumor Escape from Immune Response: Mechanisms and Targets of Activity
Current Drug Targets Interferons: Mechanisms, Biological Activities and Survey of their Use in Human Diseases
Current Bioactive Compounds Structural Basis and Therapeutic Implication of the Interaction of CCN Proteins with Glycoconjugates
Current Pharmaceutical Design PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry Advances in Nanocarriers for Anticancer Drugs Delivery
Current Medicinal Chemistry Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Patents in Cancer Stem Cells
Recent Patents on Biomarkers Saponins in Tumor Therapy
Mini-Reviews in Medicinal Chemistry Organic Nanotheranostics for Photoacoustic Imaging-Guided Phototherapy
Current Medicinal Chemistry Differentiation-Inducing Therapy for Solid Tumors
Current Pharmaceutical Design In vivo Radiosensitization of Human Glioma U87 Cells Induced by Upregulated Expression of DUSP-2 after Treatment with Curcumin
Current Signal Transduction Therapy Keeping A Breast of Recent Developments in Cancer Metabolism
Current Drug Targets Bioprocessing of Baculovirus Vectors: A Review
Current Gene Therapy Recent Progress in the Syntheses and Biological Evaluation of Boronated Porphyrins for Boron Neutron-Capture Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting the Ubiquitin-Proteasome Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry The Emerging Role of EMT-related lncRNAs in Therapy Resistance and their Applications as Biomarkers
Current Medicinal Chemistry